Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach

(2018) Erika Bereczki et al.   BRAIN

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

(2018) Charlotte E. Teunissen et al.   Alzheimers Research & Therapy

Low-Abundant Cerebrospinal Fluid Proteome Alterations in Dementia with Lewy Bodies

(2018) Jana-Katharina Dieks et al.   JOURNAL OF ALZHEIMERS DISEASE

Optimizing Patient Care and Research: The Amsterdam Dementia Cohort

(2018) Wiesje M. van der Flier et al.   JOURNAL OF ALZHEIMERS DISEASE

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies

(2018) Inger van Steenoven et al.   MOVEMENT DISORDERS

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment

(2017) Barbara Noli et al.   Frontiers in Cellular Neuroscience

NPTX2 and cognitive dysfunction in Alzheimer’s Disease

(2017) Mei-Fang Xiao et al.   eLife

Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort

(2016) Inger van Steenoven et al.   JOURNAL OF ALZHEIMERS DISEASE

Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies

(2016) Patrick Oeckl et al.   MOLECULAR & CELLULAR PROTEOMICS

Synaptic failure and α-synuclein

(2016) Laura Calo et al.   MOVEMENT DISORDERS

The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

(2016) Un Jung Kang et al.   MOVEMENT DISORDERS

The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity

(2016) Timothy S. Jarvela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lewy body dementias

(2015) Zuzana Walker et al.   LANCET

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

(2015) Wendy E. Heywood et al.   Molecular Neurodegeneration

Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo

(2014) Edward Rockenstein et al.   BRAIN

International Classification of Sleep Disorders-Third Edition

(2014) Michael J Sateia   CHEST

Biobanking of CSF: International standardization to optimize biomarker development

(2014) Charlotte E. Teunissen et al.   CLINICAL BIOCHEMISTRY

Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ

(2014) Jürgen Cox et al.   MOLECULAR & CELLULAR PROTEOMICS

VGF Changes during the Estrous Cycle: A Novel Endocrine Role for TLQP Peptides?

(2014) Barbara Noli et al.   PLoS One

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease

(2013) Akina Hoshino et al.   JOURNAL OF NEUROCHEMISTRY

Whole gel processing procedure for GeLC-MS/MS based proteomics

(2013) Sander R Piersma et al.   Proteome Science

Genome-scale proteome quantification by DEEP SEQ mass spectrometry

(2013) Feng Zhou et al.   Nature Communications

VGF peptides upon osmotic stimuli: Changes in neuroendocrine regulatory peptides 1 and 2 in the hypothalamic–pituitary-axis and plasma

(2012) Filomena D’Amato et al.   JOURNAL OF CHEMICAL NEUROANATOMY

The dynorphin/κ-opioid receptor system and its role in psychiatric disorders

(2011) H. A. Tejeda et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The Extended Granin Family: Structure, Function, and Biomedical Implications

(2011) Alessandro Bartolomucci et al.   ENDOCRINE REVIEWS

VGF: An inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers

(2011) Gian-Luca Ferri et al.   JOURNAL OF CHEMICAL NEUROANATOMY

Pathological roles of α-synuclein in neurological disorders

(2011) Kostas Vekrellis et al.   LANCET NEUROLOGY

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

(2010) Walter J. Schulz-Schaeffer   ACTA NEUROPATHOLOGICA

Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases

(2010) Cristina Cocco et al.   JOURNAL OF ANATOMY

A Pathologic Cascade Leading to Synaptic Dysfunction in  -Synuclein-Induced Neurodegeneration

(2010) D. A. Scott et al.   JOURNAL OF NEUROSCIENCE

Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons

(2010) Michael C Chang et al.   NATURE NEUROSCIENCE

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Comparison of the performance of two affinity depletion spin filters for quantitative proteomics of CSF: Evaluation of sensitivity and reproducibility of CSF analysis using GeLC-MS/MS and spectral counting

(2010) Silvina A. Fratantoni et al.   Proteomics Clinical Applications

Amyloid- (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

(2009) C. Mulder et al.   CLINICAL CHEMISTRY

30 years of dynorphins — New insights on their functions in neuropsychiatric diseases

(2009) Christoph Schwarzer   PHARMACOLOGY & THERAPEUTICS

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

(2008) Brit Mollenhauer et al.   EXPERIMENTAL NEUROLOGY

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY